Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* A male between, and including, 10 and 18 years of age at the time of the first vaccination.~* Written informed consent obtained from the subject prior to enrolment~* For subjects below the legal age of consent, a written informed consent must be obtained from the subject's parent/guardian. In addition, a written informed assent must be obtained from the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~Exclusion criteria:~* Previous vaccination against Human Papillomavirus (HPV).~* Previous vaccination against Hepatitis B, known clinical history of Hepatitis B infection.~* Cancer or autoimmune disease under treatment.

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: EXPERIMENTAL): Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
- Engerix-B Group (Type: ACTIVE_COMPARATOR): Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Engerix-B™ (HBV) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).